Evaluation of PRKACA as a Therapeutic Target for Fibrolamellar Carcinoma
S. S. Schalm, E. O'Hearn, K. Wilson, T. P. LaBranch, G. Silva, Z. Zhang, L. DiPietro, N. Bifulco, R. Woessner, N. Stransky, D. Sappal, R. Campbell, R. Lobbardi, M. Palmer, J. Kim, , K. P. Hoeflich
This study evaluates PRKACA as a therapeutic target for fibrolamellar carcinoma using PDX models and shows that its knockdown or inhibition reduces tumor growth.
bioRxiv · Jan 31, 2022 · PreprintCancer Biology